OS Therapies Incorporated OSTX 深 滬
已收盤 07-02 16:00:00 美东时间
1.89
+0.080
+4.42%
華盛通- 最 高1.93
- 今 開1.82
- 成交量 62.63万股
- 最 低 1.805
- 昨 收 1.81
- 總市值 8417.70万
- 52周最高 2.57
- 市盈率 靜 --
- 換手率 1.41%
- 52周最低 1.15
- 委 比 0.00%
- 總股本 4453.81万
- 歷史最高 7.00
- 量 比 0.54
- 振 幅 6.91%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall Survival Data Is A Clinical Endpoint
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided regulatory update on the Company's interactions with the U.S. Food and Drug Administration (FDA) in its pursuit of a Biologics License Application ...
06-30 19:45
OS疗法公司称新骨癌数据为监管申报提供有力支持
OS疗法公司（NYSE:OSTX）股价周二盘前上涨，因其宣布OST - HER2的2b期试验在2.5年节点取得有统计学意义的总体生存结果。 试验显示，肺转移骨肉...
06-02 19:29
OS Therapies Announces Its Phase 2b Trial Of OST-HER2 In The Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma Achieved Statistically Significant Benefit For OST-HER2 Treated Patients In Overall Survival At The 2.5-Year Mark
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated clinical efficacy data
06-02 18:07
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
Lake Street Maintains Buy on OS Therapies, Lowers Price Target to $13
Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the price target from $14 to $13.
05-19 22:05
Earnings Scheduled For May 18, 2026
Companies Reporting Before The Bell • Compugen (NASDAQ:CGEN) is likely to repor...
05-18 19:11
OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.18) by 50 percent. This is a 50 percent decrease over losses of $(0.18) per share from the same
05-18 18:37
OS Therapies Says EMA's CAT Initiates Continuous Evaluation Of OST-HER2 CMA Request Regulatory Dossier For Prevention Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the OST-HER2
04-30 18:10
OS Therapies Files New Patent Application Covering Immune Signature In Response Therapeutic Candidates Developed Using Listeria Monocytogenes Platform
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responsesCompany to host conference call later in April 2026
04-16 19:27
OS Therapies Q4 EPS $(0.41) Misses $(0.13) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.13) by 228 percent. This is a 70.83 percent decrease over losses of $(0.24) per share from the
03-31 19:54
